IXICO links AI neuroimaging platform with Medidata to boost CNS clinical trials

IXICO plc ( (GB:IXI) ) has provided an announcement.

IXICO has entered a technology collaboration with Medidata, a Dassault Systèmes brand and major clinical trial solutions provider, to connect its IXI Platform with the Medidata Platform and create an integrated neuroimaging data and analysis environment for clinical trials. The combined offering aims to streamline eligibility and safety reporting and centralise the collection, management and analysis of complex neuroimaging data within a secure, compliant system, potentially enhancing IXICO’s scale, co-development opportunities, and market reach while preserving its ability to work directly with biopharma clients and pursue additional partnerships.

The non-exclusive agreement is positioned as a way to expand both companies’ role in central nervous system clinical research, with Medidata’s data capabilities expected to elevate IXICO’s platform and improve the experience for contract research organisations and their biopharma sponsors. For stakeholders in neurological drug development, the collaboration is intended to accelerate and de-risk clinical research by offering a more unified and efficient neuroimaging trial workflow that could support some of the most complex and high-profile programmes in the space.

The most recent analyst rating on (GB:IXI) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.

Spark’s Take on IXI Stock

According to Spark, TipRanks’ AI Analyst, IXI is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and very bearish technicals (below key moving averages with negative MACD). A positive offset comes from supportive earnings-call guidance and order book growth, but valuation remains constrained by the company’s loss-making profile.

To see Spark’s full report on IXI stock, click here.

More about IXICO plc

IXICO plc is a London-based neuroscience imaging and biomarker analytics company that uses an proprietary AI-driven platform to support drug development in neurological disorders. Operating as an end-to-end imaging contract research organisation, it partners with global pharma, biotech, consortia and non-profits, and has supported hundreds of trials in diseases such as Alzheimer’s, Huntington’s and Parkinson’s, leveraging a worldwide network of imaging centres and specialist expertise in neuroimaging biomarkers.

Average Trading Volume: 132,955

Technical Sentiment Signal: Sell

Current Market Cap: £7.23M

Learn more about IXI stock on TipRanks’ Stock Analysis page.